Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 28Melanoma 4Sarcoma 3Liposarcoma 3Ovarian Neoplasms 2Neoplasms 2Breast Cancer Metastatic 2Thymus Neoplasms 1Teratoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma 1Locoregional Recurrence 1Liposarcoma, Myxoid 1Lipoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2 Negative Breast Cancer 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1

Interventions

lutetium Lu 177 dotatate 15Everolimus 11Nivolumab 10pembrolizumab 9Temozolomide 9Capecitabine 7cabozantinib 6Sunitinib 6lenvatinib 5lanreotide 4gallium Ga 68 dotatate 4Ipilimumab 4Etoposide 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3pazopanib 3avelumab 3Octreotide 3Magnetic Resonance Spectroscopy 3Injections 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3surufatinib 2sintilimab 2fosbretabulin 2fludarabine 2Specimen Handling 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroendocrine Tumors × ribociclib × Clear all
NCT03070301 2024-10-10

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
21 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡